Critical Conversations in Melanoma: Expert Perspectives on Immunotherapy in Resectable and Unresectable Disease

Gain expert insights on the latest evidence-based strategies incorporating immunotherapy for the management of melanoma in the neoadjuvant, adjuvant, and metastatic settings with this educational program featuring an on-demand webcast, downloadable slides, and an expert commentary.

Share

Program Content

Activities

Melanoma Conversations
Critical Conversations in Melanoma: Expert Perspectives on Immunotherapy in Resectable and Unresectable Disease
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

Activities

Melanoma: Immunotherapy in Resectable and Unresectable Disease
Critical Conversations in Melanoma: Expert Perspectives on Immunotherapy in Resectable and Unresectable Disease
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2023

Expires: June 20, 2024

Activities

Melanoma Immunotherapy FAQ
Experts Address Questions on the Use of Immunotherapy for Resectable and Unresectable Melanoma in Today’s Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2023

Faculty

cover img faculity

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

cover img faculity

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

cover img faculity

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb